408 related articles for article (PubMed ID: 25019486)
1. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
[TBL] [Abstract][Full Text] [Related]
2. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident.
Liu HT; Liu AB; Chancellor MB; Kuo HC
BJU Int; 2009 Oct; 104(8):1158-62. PubMed ID: 19338537
[TBL] [Abstract][Full Text] [Related]
3. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
4. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding.
Ergin G; Kibar Y; Ebiloğlu T; Irkılata HC; Kopru B; Kaya E; Uyanık M; Tapan S; Dayanc MM
J Pediatr Urol; 2016 Apr; 12(2):118.e1-6. PubMed ID: 26701107
[TBL] [Abstract][Full Text] [Related]
5. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence.
Groenendijk PM; Lycklama à Nyeholt AA; Heesakkers JP; van Kerrebroeck PE; Hassouna MM; Gajewski JB; Cappellano F; Siegel SW; Fall M; Dijkema HE; Jonas U; van den Hombergh U;
BJU Int; 2008 Feb; 101(3):325-9. PubMed ID: 18070199
[TBL] [Abstract][Full Text] [Related]
8. Urinary nerve growth factor in patients with symptomatic detrusor overactivity.
Agilli M; Aydin FN; Cayci T
Am J Obstet Gynecol; 2015 Feb; 212(2):251-2. PubMed ID: 25305404
[No Abstract] [Full Text] [Related]
9. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
10. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
[TBL] [Abstract][Full Text] [Related]
11. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
Kim SR; Moon YJ; Kim SK; Bai SW
Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
[TBL] [Abstract][Full Text] [Related]
12. Urethral instability and sacral nerve stimulation-a better parameter to predict efficacy?
Groenendijk PM; Heesakkers JP; Lycklama A Nijeholt AA
J Urol; 2007 Aug; 178(2):568-72; discussion 572. PubMed ID: 17570438
[TBL] [Abstract][Full Text] [Related]
13. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
Liu HT; Chancellor MB; Kuo HC
Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
[TBL] [Abstract][Full Text] [Related]
14. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
15. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
[TBL] [Abstract][Full Text] [Related]
17. Can urinary nerve growth factor and bladder wall thickness correlation in children have a potential role to predict the outcome of non-monosymptomatic nocturnal enuresis?
Telli O; Samancı C; Sarıcı H; Hascıcek AM; Kabar M; Eroglu M
J Pediatr Urol; 2015 Oct; 11(5):265.e1-5. PubMed ID: 26051999
[TBL] [Abstract][Full Text] [Related]
18. Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis.
Qu HC; Yan S; Zhang XL; Zhu XW; Liu YL; Wang P
Genet Mol Res; 2014 Apr; 13(4):8609-19. PubMed ID: 24782215
[TBL] [Abstract][Full Text] [Related]
19. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
